Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 46 | 2023 | 1188 | 4.010 |
Why?
|
| Heart-Assist Devices | 40 | 2022 | 759 | 3.700 |
Why?
|
| Cardiomyopathies | 10 | 2024 | 265 | 2.560 |
Why?
|
| Amyloidosis | 12 | 2024 | 130 | 2.420 |
Why?
|
| Hemodynamics | 18 | 2022 | 731 | 1.590 |
Why?
|
| Amyloid Neuropathies, Familial | 5 | 2024 | 27 | 1.460 |
Why?
|
| Ventricular Function, Left | 14 | 2024 | 607 | 1.200 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 113 | 0.950 |
Why?
|
| Heart Transplantation | 7 | 2023 | 717 | 0.900 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 303 | 0.790 |
Why?
|
| Heart Ventricles | 10 | 2024 | 779 | 0.760 |
Why?
|
| Prealbumin | 6 | 2023 | 34 | 0.760 |
Why?
|
| Diflunisal | 1 | 2020 | 1 | 0.730 |
Why?
|
| Heart Valve Diseases | 3 | 2024 | 115 | 0.730 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 4 | 2024 | 24 | 0.700 |
Why?
|
| Echocardiography | 9 | 2024 | 938 | 0.640 |
Why?
|
| Middle Aged | 50 | 2024 | 26069 | 0.540 |
Why?
|
| Retrospective Studies | 29 | 2024 | 9089 | 0.510 |
Why?
|
| Male | 56 | 2024 | 42558 | 0.510 |
Why?
|
| Humans | 74 | 2024 | 89621 | 0.480 |
Why?
|
| Aged | 38 | 2024 | 19237 | 0.470 |
Why?
|
| Female | 53 | 2024 | 46354 | 0.460 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2022 | 78 | 0.450 |
Why?
|
| Prosthesis Implantation | 3 | 2019 | 126 | 0.430 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2021 | 132 | 0.430 |
Why?
|
| Prospective Studies | 15 | 2022 | 4310 | 0.410 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 106 | 0.360 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 236 | 0.340 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 330 | 0.330 |
Why?
|
| Azithromycin | 1 | 2009 | 13 | 0.330 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 37 | 0.320 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 192 | 0.310 |
Why?
|
| Myocarditis | 1 | 2009 | 51 | 0.310 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 96 | 0.300 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 186 | 0.300 |
Why?
|
| Thromboembolism | 2 | 2018 | 120 | 0.290 |
Why?
|
| Thrombosis | 2 | 2020 | 302 | 0.290 |
Why?
|
| Device Removal | 2 | 2019 | 168 | 0.290 |
Why?
|
| Hemorrhage | 2 | 2018 | 284 | 0.270 |
Why?
|
| Cannula | 4 | 2019 | 50 | 0.260 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 237 | 0.260 |
Why?
|
| Treatment Outcome | 15 | 2023 | 8273 | 0.260 |
Why?
|
| Heart Function Tests | 2 | 2018 | 33 | 0.250 |
Why?
|
| Cardiotonic Agents | 2 | 2019 | 89 | 0.240 |
Why?
|
| Cardiac Output | 3 | 2022 | 155 | 0.230 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 14 | 0.220 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 1728 | 0.220 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 25 | 0.220 |
Why?
|
| Graft Rejection | 2 | 2020 | 1072 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 790 | 0.220 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 26 | 0.210 |
Why?
|
| Anticoagulants | 4 | 2019 | 428 | 0.210 |
Why?
|
| Postoperative Complications | 5 | 2022 | 2286 | 0.210 |
Why?
|
| Stroke Volume | 3 | 2023 | 465 | 0.210 |
Why?
|
| Benzoxazoles | 1 | 2022 | 4 | 0.210 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 49 | 0.200 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.200 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 113 | 0.200 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 557 | 0.190 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 178 | 0.190 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 516 | 0.190 |
Why?
|
| Aortic Rupture | 1 | 2022 | 57 | 0.190 |
Why?
|
| Prognosis | 7 | 2024 | 3796 | 0.190 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 94 | 0.190 |
Why?
|
| Lactic Acid | 1 | 2021 | 92 | 0.180 |
Why?
|
| Arterial Pressure | 2 | 2018 | 38 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 87 | 0.180 |
Why?
|
| Ventricular Function, Right | 2 | 2018 | 146 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 977 | 0.180 |
Why?
|
| Rare Diseases | 1 | 2020 | 70 | 0.180 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 27 | 0.170 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 19 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6834 | 0.170 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.170 |
Why?
|
| Heart | 2 | 2023 | 574 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 124 | 0.170 |
Why?
|
| Electric Impedance | 1 | 2020 | 110 | 0.170 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 319 | 0.170 |
Why?
|
| Sternotomy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 8 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 105 | 0.160 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.160 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2020 | 137 | 0.160 |
Why?
|
| Enoxaparin | 1 | 2018 | 23 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 51 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2020 | 253 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 276 | 0.150 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 69 | 0.150 |
Why?
|
| Octreotide | 1 | 2018 | 26 | 0.150 |
Why?
|
| Patient Readmission | 2 | 2019 | 353 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 166 | 0.150 |
Why?
|
| Adult | 16 | 2020 | 26694 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2022 | 2878 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 19 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2019 | 353 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 158 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 433 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2018 | 187 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 282 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3671 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2018 | 298 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 145 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 415 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 5344 | 0.130 |
Why?
|
| Serotonin | 1 | 2016 | 221 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Survival Rate | 4 | 2024 | 1909 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1720 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1171 | 0.120 |
Why?
|
| Incidence | 4 | 2021 | 1598 | 0.120 |
Why?
|
| Risk Factors | 6 | 2024 | 5516 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 880 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2024 | 91 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 852 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2018 | 2305 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2019 | 388 | 0.110 |
Why?
|
| Carney Complex | 1 | 2012 | 2 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 742 | 0.100 |
Why?
|
| Prosthesis Design | 3 | 2019 | 298 | 0.100 |
Why?
|
| Lung | 1 | 2018 | 1266 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2015 | 497 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 856 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 690 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 364 | 0.100 |
Why?
|
| Recurrence | 3 | 2018 | 1144 | 0.090 |
Why?
|
| Decision Trees | 1 | 2010 | 59 | 0.090 |
Why?
|
| Causality | 1 | 2010 | 80 | 0.090 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 66 | 0.080 |
Why?
|
| Diuretics | 1 | 2010 | 75 | 0.080 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 56 | 0.080 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2023 | 162 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 91 | 0.080 |
Why?
|
| Prevalence | 2 | 2024 | 1246 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 61 | 0.080 |
Why?
|
| Azathioprine | 1 | 2009 | 124 | 0.080 |
Why?
|
| Prednisone | 1 | 2009 | 259 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 217 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2018 | 120 | 0.070 |
Why?
|
| Aortic Valve | 2 | 2021 | 244 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 785 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2019 | 293 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2009 | 358 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 951 | 0.070 |
Why?
|
| Disease Progression | 2 | 2021 | 1492 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1601 | 0.060 |
Why?
|
| Amyloidosis, Familial | 1 | 2023 | 2 | 0.060 |
Why?
|
| Amyloid | 1 | 2024 | 95 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 155 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2024 | 107 | 0.060 |
Why?
|
| Biomarkers | 2 | 2022 | 1770 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Technetium | 1 | 2022 | 29 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 97 | 0.050 |
Why?
|
| Gadolinium | 1 | 2023 | 103 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 77 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 314 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 184 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 780 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 148 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1890 | 0.050 |
Why?
|
| Myocardium | 1 | 2024 | 572 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 265 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 496 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 28 | 0.040 |
Why?
|
| Heart Atria | 1 | 2022 | 281 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 55 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 288 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2017 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2024 | 1863 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 360 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 298 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1722 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 75 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 142 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 183 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 469 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 50 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 185 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 115 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 322 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 1210 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 143 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 289 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2018 | 131 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2763 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 64 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 39 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 148 | 0.040 |
Why?
|
| Contrast Media | 1 | 2023 | 1092 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 285 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 353 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 110 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 196 | 0.040 |
Why?
|
| Neutropenia | 1 | 2018 | 216 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 241 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2010 | 712 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 360 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 145 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 684 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 602 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 33 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 783 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 483 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 172 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 116 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 270 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1535 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 864 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1428 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 661 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 419 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 166 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 988 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1217 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 612 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 775 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1944 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1068 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 689 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1874 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 987 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2641 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4162 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 36 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 54 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 234 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 950 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7020 | 0.020 |
Why?
|
| Adolescent | 1 | 2012 | 9288 | 0.010 |
Why?
|